 |
Indication & Dosage |
| |
| |
| Oral |
| HIV INFECTION |
| Adult:
<60: 30 mg; ≥60 kg: 40 mg. Doses to be taken every 12 hr. |
| |
| Oral |
| HIV INFECTION |
| Child:
From birth-13 days old: 500 mcg/kg; ≥14 days old and weighing <30 kg: 1 mg/kg; 30 kg-<60 kg: 30 mg; ≥60 kg: 40 mg. Doses to be taken every 12 hr. |
|
| |
|
| Administration |
May be taken with or without food. |
| |
|
| Precautions |
Hepatomegaly or other risk factors for liver disease. History of peripheral neuropathy and renal impairment. Pregnancy. Discontinue treatment if peripheral neuropathy develops; may resume treatment at half the previous dose if symptoms resolve upon drug withdrawal. Monitor for signs of pancreatitis. Discontinue treatment if there is a rapid increase in aminotransferase concentrations, progressive hepatomegaly or steatosis, or metabolic or lactic acidosis. Increased risk of severe and fatal hepatic adverse events in patients with chronic hepatitis B or C treated with combination antiretroviral therapy. |
| |
|
| Adverse Drug Reactions |
Headache, nausea, vomiting, asthenia, chest pain, influenza-like syndrome, insomnia, abdominal pain, anorexia, neutropenia, thrombocytopenia, arthralgia, myalgia, mood changes, dyspnoea, pharyngitis, skin rashes, pruritus. |
| |
|
| Interactions |
Antiviral effect inhibited by zidovudine, doxorubicin and ribavirin. Avoid concurrent admin with drugs that cause pancreatitis (e.g. IV pentamidine) or peripheral neuropathy (e.g. metronidazole, isoniazid and vincristine). Increased risk of adverse effects such as hepatoxicity, peripheral neuropathy and pancreatitis if used with hydroxycarbamide and didanosine. |
| |
|
|
|
